Symposium Co-Chairs
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
The University of Texas M. D. Anderson Cancer Center
Houston, TX
Rafael Rosell, MD, PhD
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
Vincent A. Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Jyoti D. Patel, MD
Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR
Co-Chair, Lung Committee, Eastern Cooperative Oncology Group (ECOG)
|
|
Emerging Novel Strategies for Personalized Initial and Maintenance Therapy of NSCLC: Critical Questions Addressed by the Experts
|
|
PLEASE NOTE:
Pre-registration is now available on a "stand-by" basis only. We have received the maximum number of 400 confirmed pre-registrants. We do expect that approximately 50 pre-registrants will not attend. So if you are interested in attending this symposium please register now as a "stand-by" pre-registrant. At 6:30PM on June 5, 2010 "standy-by" registrants can attend the symposium on a first-come basis. Thank you.
June 5, 2010 | Chicago IL
Hyatt Regency McCormick Place
Conference Center Rooms 10-A, B, C, D
2233 South Martin Luther King Drive
Chicago, IL 60616
6 PM - 6:30PM Registration and Dinner
6:30PM - 8:30PM CME Symposium
Taught by the top academic experts in NSCLC this is THE symposium on NSCLC that you should attend in 2010.
|
|
|
CO-CHAIRS
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
The University of Texas M. D. Anderson Cancer Center
Houston, TX
Rafael Rosell, MD, PhD
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
|
|
|
|
| Overview |
Back to Top |
|
This CME symposium will use a faculty consisting of five scientific and clinical NSCLC experts from the USA and Europe to present, review, and discuss how to employ novel anti-EGFR and anti-angiogenic therapies into their treatment strategies for initial and maintenance therapy for this malignancy.
To make this symposium as interactive as possible each of the presentations is posed as a critical question and begins with either an interactive case study or a clinical treatment related question. The audience selects treatments with multiple-choice answers to the questions.
Following each presentation will be a 10-minute Interactive Roundtable Discussion during which the other expert faculty members provide their individual perspectives addressing the specific critical question. During the final Interactive Roundtable Discussion the audience may ask questions of the faculty.
|
|
| |
|
| Educational Statement of Need |
Back to Top |
|
During the past year clinical data has emerged resulting in practice-changing paradigm shifts for the treatment and management of patients with NSCLC. This is especially relevant for initial and maintenance therapy of NSCLC with novel strategies targeting EGFR and inhibiting angiogenesis. As a result, with these newer therapeutic options several critical questions need to be addressed to help physicians treat and manage their NSCLC patients with the optimal personalized strategies using targeted therapies.
|
|
|
|
|
|
This symposium is designed for medical oncologists, hematologist/oncologists, radiation oncologists, surgical oncologists, pathologists, nurse practitioners/nurses, pharmacists, fellows and other health care professionals who are involved in the treatment or management of patients with NSCLC. This malignancy is treated optimally by a multi-disciplinary approach of clinicians and, thus, they are all targeted for invitation to this symposium.
|
|
|
|
|
The following learning objectives were derived from our physician practice gap analysis and needs assessment. At the conclusion of this symposium, and/or after reviewing the enduring materials, participants will be able to:
- Devise strategies for optimally personalizing targeted therapies for nonsquamous NSCLC patients with advanced or metastatic disease.
- Compare and contrast the new scientific and clinical data regarding the various targeted therapy options for maintenance therapy for nonsquamous NSCLC and determine how to best utilize these strategies.
- Devise optimal initial therapy strategies for mutation-positive NSCLC patients.
- Determine how to best treat patients with nonsquamous NSCLC with combinations of angiogenesis and EGFR inhibition strategies.
|
|
|
|
|
The Oncology Learning Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Oncology Learning Center designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse practitioners, nurses, pharmacists and Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.
|
|
|
|
| DISCLOSURE STATEMENT AND RESOLUTION OF ANY CONFLICTS OF INTEREST |
|
Not an official event of the ASCO Annual Meeting. Not sponsored or endorsed by ASCO or The ASCO Cancer Foundation.
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, all educational programs sponsored by the Oncology Learning Center (OLC) demonstrate fair balance, complete independence from any commercial supporters, objectivity, and scientific rigor. All faculty, authors, editors, OLC staff and planning committee members participating in an educational activity who are in control of content or in communication with faculty are required to disclose any relevant financial interest or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an OLC educational activity. All disclosures will be made available to all activity participants prior to the conduct of its educational activity. In addition, all conflicts of interest will be resolved prior to the conduct of its educational activity.
|
| DISCLOSURE OF UNLABELED USE |
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Oncology Learning Center does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Oncology Learning Center. Please refer to the official prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
|
| DISCLAIMER |
Participants of OLC's educational activities have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development and practices. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. |
|
| Educational Grants |
Sincere appreciation is extended to Genentech for their generous commercial support of this educational meeting. |
|
|
|
